Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13849154 | 0.98 | HRH3 (0.61) | HRH3ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL10103385 | 0.98 | HRH3 (0.61) | HRH3ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL21472087 | 0.96 | HRH3 (0.65) | HRH3ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL1277016 | 0.93 | HRH3 (0.52) | HRH3ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL2331849 | 0.91 | HRH3 (0.56) | HRH3ALDH1A1CYP2D6L3MBTL1MAPT | |
| SCHEMBL96486 | 0.91 | HRH3 (0.56) | HRH3ALDH1A1CYP2D6L3MBTL1MAPT | |
| SCHEMBL11574905 | 0.90 | — | — | |
| SCHEMBL11570576 | 0.88 | HRH3 (0.46) | HRH3ALDH1A1 | |
| SCHEMBL10927336 | 0.88 | HRH3 (0.46) | HRH3ALDH1A1 | |
| SCHEMBL11569007 | 0.88 | HRH3 (0.46) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854402-A1 | TREATMENT OR PREVENTION OF TRANSPLANT REJECTION | CTI Biopharma Corp. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3181554-B1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-08-10 | — | — | US | disclosed |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | ALLERGAN, INC. | 2016-07-14 | — | — | US | disclosed |
| WO-2016023330-A1 | QUINAZOLINE DERIVATIVE | 石药集团中奇制药技术（石家庄）有限公司 | 2016-02-18 | — | — | WO | disclosed |
| US-9233070-B2 | Biodegradable intravitreal tyrosine kinase implants | ALLERGAN, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9056045-B2 | Intraocular biodegradable microspheres | ALLERGAN, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-8968766-B2 | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods | ALLERGAN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8835643-B2 | Molecules, compositions, and methods for light absorption | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140193348-A1 | MOLECULES, COMPOSITIONS, AND METHODS FOR LIGHT ABSORPTION | CRESTLINE DIRECT FINANCE, L.P. | 2014-07-10 | — | — | US | disclosed |
| EP-2142189-B1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7771742-B2 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer; pharmacokinetics | ALLERGAN, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1519915-B1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080260803-A1 | Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer | ALLERGAN,INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | ALLERGAN,INC (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008121665-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | ALLERGAN, INC. (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | HRH3 1844/4885ALDH1A1 563/4885MEN1 4825/4885 |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | HRH3 3184/4885ALDH1A1 1951/4885MEN1 319/4885 |
| US-20140193348-A1 | MOLECULES, COMPOSITIONS, AND METHODS FOR LIGHT ABSORPTION | CRY1, ERCC1, CRY2 | HRH3 4509/4885ALDH1A1 77/4885MEN1 966/4885 |
| US-20170226099-A1 | QUINAZOLINE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 | HRH3 1955/4885ALDH1A1 2644/4885MEN1 2146/4885 |
| US-20160199297-A1 | BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS | KDR, PTK2B, DSTYK | HRH3 2521/4885ALDH1A1 1537/4885MEN1 3082/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | HRH3 3336/4885ALDH1A1 1497/4885MEN1 4800/4885 |
| US-20080254096-A1 | Using polyvinyl alcohol free biodegradable polymer matrix; reducing side effects, invasive procedures and high transient concentrations; glaucoma, proliferative vitreoretinopathy | VEGFA, PTK2, KDR | HRH3 3764/4885ALDH1A1 1521/4885MEN1 1851/4885 |
| US-20080241252-A1 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS | FLT1, JAK1, KDR | HRH3 4038/4885ALDH1A1 4379/4885MEN1 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.